While the clinical impact of GLP-1s on approved indications (e.g., obesity, diabetes, cardiovascular risk) and adjacent indications is being studied extensively in clinical trials, there is limited scientific literature on GLP-1 use, efficacy or persistence outside of clinical trial settings
This helps us craft a personalized weight loss plan thats tailored to your unique needs
It is not medical advice or a treatment plan
According to the Ozempic prescribing information, it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
GAPDH, detected on the same blot, was used as loading control